NVO Novo Nordisk

  1. Stocks
  2. Healthcare
  3. NYSE: NVO

Price (delayed)

$43.93

Market cap

$196.15B

P/E Ratio

10.43

Dividend/share

$1.86

EPS

27.45 DKK

Enterprise value

$215.36B

?
Relative Growth: Rel. Growth: 96
Relative Strength: Rel. Strength: 27
Relative Valuation: Rel. Valuation: 83
Relative Profitability: Rel. Profitability: 98

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The ...

Highlights
The stock's P/E is 67% less than its 5-year quarterly average of 31.2 and 25% less than its last 4 quarters average of 13.9
The equity has increased by 47% year-on-year and by 4.6% since the previous quarter
NVO's quick ratio is up by 2.2% since the previous quarter but it is down by 2.1% year-on-year
The debt has grown by 23% year-on-year and by 12% since the previous quarter
NVO's gross margin is down by 3% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: http://www.novonordisk.com
Peers: MRK BMY AMGN LLY

Key stats

What are the main financial stats of NVO

NVO stock price

How has the Novo Nordisk stock price performed over time
Intraday
0.11%
1 week
7.09%
1 month
-1.81%
1 year
-44.97%
YTD
-13.66%
QTD
19.54%

Financial performance

How have Novo Nordisk's revenue and profit performed over time
Revenue
327.8B DKK
Gross profit
268.3B DKK
Operating income
148.49B DKK
Net income
121.96B DKK
Gross margin
81.8%
Net margin
37.2%
NVO's net income is up by 19% since the previous quarter and by 17% year-on-year
NVO's operating income is up by 16% QoQ and by 10% YoY
The net margin has grown by 12% since the previous quarter and by 8% year-on-year
The company's operating margin rose by 10% QoQ

Price vs fundamentals

How does NVO's price correlate with its fundamentals

Growth

What is Novo Nordisk's growth rate over time

Valuation

What is Novo Nordisk stock price valuation
NVO P/E details
P/E
10.43
P/B
6.3
P/S
3.9
EV/EBIT
9.02
EV/EBITDA
7.92
EV/Sales
4.28
The stock's P/E is 67% less than its 5-year quarterly average of 31.2 and 25% less than its last 4 quarters average of 13.9
Novo Nordisk's EPS has increased by 19% from the previous quarter and by 17% YoY
NVO's price to book (P/B) is 73% lower than its 5-year quarterly average of 23.1 and 25% lower than its last 4 quarters average of 8.4
The equity has increased by 47% year-on-year and by 4.6% since the previous quarter
The P/S is 64% lower than the 5-year quarterly average of 10.7 and 19% lower than the last 4 quarters average of 4.8
The revenue has grown by 8% year-on-year and by 6% since the previous quarter

Efficiency

How efficient is Novo Nordisk business performance
The ROIC is down by 25% year-on-year but it is up by 8% since the previous quarter
Novo Nordisk's ROE has decreased by 18% YoY but it has increased by 9% from the previous quarter
Novo Nordisk's return on assets has increased by 15% QoQ but it has decreased by 4.1% YoY
Novo Nordisk's ROS has increased by 13% from the previous quarter and by 9% YoY

Dividends

What is NVO's dividend history
Dividend details
DPS
$1.86
Dividend yield
4.23%
Payout ratio
44.2%
Recent dividends

Special dividends are included in TTM DPS and yield

Financial health

How did Novo Nordisk financials performed over time
Novo Nordisk's total assets is 57% more than its total liabilities
Novo Nordisk's total assets has increased by 14% YoY and by 3% from the previous quarter
Novo Nordisk's current ratio has increased by 7% YoY
The debt is 28% smaller than the equity
The equity has increased by 47% year-on-year and by 4.6% since the previous quarter
The debt has grown by 23% year-on-year and by 12% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.